Non-invasive diagnosis of liver fibrosis in patients with comorbid course non-alcoholic fatty liver disease and hypertension

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic disease, an independent risk factor for cardiovascular disease and a basis for the progression of all metabolic syndrome’s manifestations (hypertension, insulin resistance, diabetes, etc.). The BARD scale is a prognostic model that, according to the literature, has a high sensitivity and specificity and can be used to assess the intensity of the liver fibrotic process in patients with NAFLD. The BARD scale can used at management of different stages in patients with NAFLD. It is an effective tool for outpatient assessment of the risk and fibrotic process intensity in the liver and can be a dynamic marker of this process. The presence of concomitant hypertension adversely affects the course of NAFLD, causing an increased risk of liver fibrosis in such patients.